AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ - AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partnerSpectrum Pharmaceuticals presented an abstract outlining detailedPhase 2 results for AEterna Zentaris' fourth-generation luteinizinghormone-r...
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at
Annual Meeting of American Urological Association
*
Ozarelix Effective in Improving Symptoms and Urine Flow, WithLong Lasting Effect in Phase 2 Study IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- SpectrumPharmaceuticals, Inc., today announced Phase 2 safety and efficacydata for
ozarelix, the Company's drug candidate for the treatmentof benign prostatic hypertrophy (BPH), at the American UrologyAssociation Annual Meeting held at...